Programmed Death Ligand-1 Immunohistochemistry: Friend or Foe?
Open Access
- 12 January 2016
- journal article
- Published by Archives of Pathology and Laboratory Medicine in Archives Of Pathology & Laboratory Medicine
- Vol. 140 (4), 326-331
- https://doi.org/10.5858/arpa.2015-0522-sa
Abstract
The approval of anti-programmed death receptor (PD)-1 therapies for non–small cell lung cancer has directed the spotlight on programmed death ligand-1 (PD-L1) immunohistochemistry as the latest predictive biomarker potentially required in this disease. Several other drugs in this class will likely be approved in the future and each has been developed with a unique anti–PD-L1 immunohistochemistry test. The prospect of 5 drugs competing in the same treatment area, each possibly requiring PD-L1 immunohistochemistry testing, presents a challenge for pathologists unlike any previously faced. The key issue is whether laboratories will attempt to deliver the trial-validated assays for one or more of these treatments, or introduce instead one or more laboratory developed tests, or attempt to provide a single PD-L1 immunohistochemistry assay for all possible anti–PD-1 and anti–PD-L1 treatments that may be used. This paper discusses some of the issues, challenges, hazards, and possible solutions that have recently emerged in this most complex interface between cancer therapeutics and laboratory biomarker testing.Keywords
This publication has 29 references indexed in Scilit:
- Complementary Versus Companion Diagnostics: Apples and Oranges?Biomarkers in Medicine, 2015
- Programmed cell death-ligand 1 expression in surgically resected stage I pulmonary adenocarcinoma and its correlation with driver mutations and clinical outcomesEuropean Journal Of Cancer, 2014
- Towards the introduction of the ‘Immunoscore’ in the classification of malignant tumoursThe Journal of Pathology, 2013
- Oncology Meets Immunology: The Cancer-Immunity CycleImmunity, 2013
- Predictive Gene Signature in MAGE-A3 Antigen-Specific Cancer ImmunotherapyJournal of Clinical Oncology, 2013
- Harnessing the Immune System for the Treatment of Non–Small-Cell Lung CancerJournal of Clinical Oncology, 2013
- Diagnosis of Lung Cancer in Small Biopsies and Cytology: Implications of the 2011 International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society ClassificationArchives Of Pathology & Laboratory Medicine, 2012
- Immuno-oncology: understanding the function and dysfunction of the immune system in cancerAnnals Of Oncology, 2012
- The blockade of immune checkpoints in cancer immunotherapyNature Reviews Cancer, 2012
- Cancer Immunoediting: Integrating Immunity’s Roles in Cancer Suppression and PromotionScience, 2011